---
layout: post
title: "Prospective Grant of Exclusive Patent License: Antibody-Based Therapeutics and Chimeric Antigen Receptors Targeting Glypican-2"
date: 2026-02-05 19:08:14 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2020-01154
original_published: 2020-01-24 00:00:00 +0000
significance: 8.00
---

# Prospective Grant of Exclusive Patent License: Antibody-Based Therapeutics and Chimeric Antigen Receptors Targeting Glypican-2

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** January 24, 2020 00:00 UTC
**Document Number:** 2020-01154

## Summary

The National Cancer Institute (NCI), National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive, sublicensable patent license to Stanford University, ("Stanford"), a non-profit university located in California, in its rights to the inventions and patents listed in the SUPPLEMENTARY INFORMATION section of this notice.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2020/01/24/2020-01154/prospective-grant-of-exclusive-patent-license-antibody-based-therapeutics-and-chimeric-antigen)
- API: https://www.federalregister.gov/api/v1/documents/2020-01154

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
